MedPath
Found 11 clinical trials|View Analysis
Sort by:

PM8002 in Combination With Paclitaxel Compared With Chemotherapy as Second-line Treatment in Small Cell Lung Cancer

Phase 3
Recruiting
Conditions
SCLC
Interventions
First Posted Date
2024-09-27
Last Posted Date
2024-12-19
Lead Sponsor
Biotheus Inc.
Target Recruit Count
404
Registration Number
NCT06616532
Locations
🇨🇳

Jilin Provincial Tumor Hospital, Changchun, China

🇨🇳

Affiliated Hospital of Nantong University, Nantong, Jiangsu, China

🇨🇳

The First Affiliated Hospital Of Ningbo University, Ningbo, Zhejiang, China

and more 8 locations

A Clinical Trial to Evaluate of PM8002 Combined With PM1009 in Patients With First-line HCC

Phase 1
Not yet recruiting
Conditions
HCC
Liver Cancer
Interventions
Drug: PM8002
Drug: atezolizumab
Drug: PM1009
Drug: bevacizumab
First Posted Date
2024-09-04
Last Posted Date
2024-12-16
Lead Sponsor
Biotheus Inc.
Target Recruit Count
140
Registration Number
NCT06584071

PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic Triple-negative Breast Cancer

Phase 3
Recruiting
Conditions
Triple Negative Breast Cancer(TNBC)
Interventions
Drug: PM8002
Drug: Placebo
Drug: Nab-Paclitaxel
First Posted Date
2024-05-17
Last Posted Date
2024-12-03
Lead Sponsor
Biotheus Inc.
Target Recruit Count
360
Registration Number
NCT06419621
Locations
🇨🇳

The first affiliated hospital of bengbu medical University, Bengbu, Anhui, China

🇨🇳

The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China

🇨🇳

Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China

and more 67 locations

A Study of PM8002 Plus Nab-paclitaxel as First Line Therapy for TNBC

Phase 1
Recruiting
Conditions
TNBC
Interventions
First Posted Date
2023-06-26
Last Posted Date
2024-12-03
Lead Sponsor
Biotheus Inc.
Target Recruit Count
60
Registration Number
NCT05918133
Locations
🇨🇳

The First Affiliated Hospital of Chongqing Medical University, Chongqing, Chongqing, China

🇨🇳

Affiliated Cancer Hospital of Harbin Medical University, Harbin, Heilongjiang, China

🇨🇳

Jiangsu Province Hospital, Nanjing, Jiangsu, China

and more 5 locations

PM8002 in the Treatment of Patients With Advanced Solid Tumors

Phase 1
Recruiting
Conditions
Malignant Neoplasm
Interventions
Drug: PM8002
First Posted Date
2023-06-26
Last Posted Date
2024-12-05
Lead Sponsor
Biotheus Inc.
Target Recruit Count
380
Registration Number
NCT05918445
Locations
🇨🇳

Shanghai Orient Hospital, Shanghai, Shanghai, China

🇨🇳

Baoji Central Hospital, Baoji, China

🇨🇳

Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China

and more 11 locations

A Study of PM8002 Injection in Combination With Standard Chemotherapy as First Line Therapy in MPM

Phase 2
Recruiting
Conditions
MPM
Interventions
First Posted Date
2023-06-26
Last Posted Date
2023-06-27
Lead Sponsor
Biotheus Inc.
Target Recruit Count
55
Registration Number
NCT05918107
Locations
🇨🇳

Jilin Provincial Tumor Hospital, Changchun, China

A Study of PM8002 in Combination With Chemotherapy in Patients With SCLC

Phase 2
Active, not recruiting
Conditions
SCLC
Interventions
Drug: PM8002
Drug: Paclitaxel
First Posted Date
2023-05-30
Last Posted Date
2024-12-18
Lead Sponsor
Biotheus Inc.
Target Recruit Count
99
Registration Number
NCT05879068
Locations
🇨🇳

Peking University Cancer Hospital, Beijing, China

🇨🇳

Hunan Cancer Hospital, Changsha, China

🇨🇳

Sichuan Provincial People's Hospital, Chengdu, China

and more 8 locations

A Study of PM8002 in Combination With Chemotherapy in Patients With NEN

Phase 2
Recruiting
Conditions
Neuroendocrine Neoplasm
Interventions
Drug: PM8002
Drug: FOLFIRI
First Posted Date
2023-05-30
Last Posted Date
2024-12-19
Lead Sponsor
Biotheus Inc.
Target Recruit Count
60
Registration Number
NCT05879055
Locations
🇨🇳

Chongqing University Cancer Hospital, Chongqing, Chongqing, China

🇨🇳

Fujian Province Cancer Hospital, Fuzhou, Fujian, China

🇨🇳

Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China

and more 10 locations

PM8002 in Combination With Chemotherapy as First Line Therapy in Hepatocellular Carcinoma

Phase 2
Recruiting
Conditions
Hepatocellular Carcinoma
Interventions
Biological: PM8002
Drug: FOLFOX regimen
First Posted Date
2023-05-18
Last Posted Date
2023-05-22
Lead Sponsor
Biotheus Inc.
Target Recruit Count
35
Registration Number
NCT05864105
Locations
🇨🇳

Cancer Hospital of The University of Chinese Academy of Sciences, Hangzhou, Zhejiang, China

A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With ES-SCLC

Phase 2
Recruiting
Conditions
SCLC
Interventions
First Posted Date
2023-05-06
Last Posted Date
2024-12-11
Lead Sponsor
Biotheus Inc.
Target Recruit Count
445
Registration Number
NCT05844150
Locations
🇨🇳

Beijing Cancer Hospital, Beijing, China

🇨🇳

The First Affiliated Hospital of Chongqing Medical University, Chongqing, China

🇨🇳

The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China

and more 14 locations
© Copyright 2025. All Rights Reserved by MedPath